CIRS-Seq was developed to investigate the complexity of secondary RNA structures in the mammalian transcriptome. CIRS-Seq uses DMS to methylate the N1 of adenosine and N3 of cytosine residues, and CMC to modify pseudouridines selectively, but only when they are in single-stranded conformation. Modifications on these nucleotide residues halt the RT process, effectively producing a truncated cDNA as a marker for the location of secondary RNA structures. Briefly, cells are lysed and treated with proteinase K to dissociate protein-bound RNAs while leaving RNA secondary structures intact. The lysates are separated into 3 different treatment lines—DMS, CMC, and no treatment. In all 3 treatment lines, total RNA is extracted and reverse-transcribed using random primers. The resulting cDNA is isolated, ligated to sequencing adapters, and subjected to high-throughput sequencing. Reads from the DMS and CMC lines are used to identify the locations of secondary RNA structures, while the control is used to reduce background noise.